News Brain infection would be bad news for Roche's MS drug Ocrevu... Suggestion is that PML case was caused by previous treatment.
News Data keeps Lilly in race for new migraine treatment Company still in race to develop CGRP inhibitor for migraine.
Views & Analysis Novartis: UK market access starting to resemble austerity-hi... The new head of Novartis UK thinks the country has gone backwards in terms of access to medicines.
News Sandoz buys into Durect's long-acting painkiller Sandoz has signed a potential $293 million agreement to develop and market Durect’s Posimir, an extended-release, locally-acting, non-opioid painkiller in the US.
News Novartis takes option on NASH drug from Conatus Swiss pharma takes option on FXR agonist emricasan.
News Valeant's Siliq price undercuts rivals to offset black box w... Siliq will be cheaper than rivals from Novartis and Eli Lilly.
Oncology ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C... At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
